Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-07-01

Clinical Trial Update: RDEA3170 Monotherapy in Subjects With Gout [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 monotherapy trial of RDEA3170 in subjects with gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RDEA3170 (RDEA3170)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 2 | Status: COMPLETED